This technology involves an oral available developmental drug candidate, DBPR728, that demonstrated in vivo efficacy in promoting the degradation of the MYC oncoprotein and inhibiting glycolysis of cancer cells, thereby inducing cancer cell apoptosis. Clinically, this technology primarily targets diseases such as small cell lung cancer and triple-negative breast cancer, which acquired MYC gene amplification.
Development of an Implantable Bioelectronic Platform for the Peripheral Neuromuscular System Regeneration
A Wearable and Self-powered Multifunctional Module for Active Infectio n Prevention, Accelerated Wound Healing and Noninvasive Healing Moni toring
Direct Reprogramming of Human Fibroblasts into Retinal Progenitor Cells by Small Molecules to Treat Photoreceptor Degeneration Induced Blindness
Novel Autopilot Jet-Based Electrospinning for Fabricating Functional 3D Scaffolds for Tissue Engineering and Regenerative Medicine Applications
Technology maturity：Prototype
Exhibiting purpose：Display of scientific results
Trading preferences：Negotiate by self
Coming soon!